NASDAQ:ZURA Zura Bio (ZURA) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free ZURA Stock Alerts $2.57 +0.25 (+10.78%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.25▼$2.6050-Day Range$2.05▼$4.3052-Week Range$2.00▼$18.93Volume216,611 shsAverage Volume281,670 shsMarket Capitalization$110.74 millionP/E RatioN/ADividend YieldN/APrice Target$16.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Zura Bio alerts: Email Address Zura Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.20 Rating ScoreUpside/Downside545.9% Upside$16.60 Price TargetShort InterestHealthy1.75% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.83Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.15) to ($0.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.63 out of 5 starsMedical Sector273rd out of 938 stocksBiological Products, Except Diagnostic Industry33rd out of 153 stocks 3.6 Analyst's Opinion Consensus RatingZura Bio has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.60, Zura Bio has a forecasted upside of 545.9% from its current price of $2.57.Amount of Analyst CoverageZura Bio has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.75% of the float of Zura Bio has been sold short.Short Interest Ratio / Days to CoverZura Bio has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zura Bio has recently decreased by 7.87%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldZura Bio does not currently pay a dividend.Dividend GrowthZura Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZURA. Previous Next 3.2 News and Social Media Coverage News SentimentZura Bio has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Zura Bio this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for ZURA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows9 people have added Zura Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zura Bio insiders have not sold or bought any company stock.Percentage Held by Insiders15.80% of the stock of Zura Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.14% of the stock of Zura Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zura Bio are expected to grow in the coming year, from ($2.15) to ($0.98) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About Zura Bio Stock (NASDAQ:ZURA)Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.Read More ZURA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZURA Stock News HeadlinesMarch 28, 2024 | businesswire.comZura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive OfficerMarch 27, 2024 | americanbankingnews.comZura Bio (NASDAQ:ZURA) Trading Down 5.8%March 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 27, 2024 | americanbankingnews.comZura Bio (NASDAQ:ZURA) Stock Price Down 5.8%March 4, 2024 | businesswire.comZura Bio Announces Participation at March ConferencesFebruary 14, 2024 | finance.yahoo.comWe're Not Very Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn RateFebruary 3, 2024 | msn.comZura Bio Issues Regulation FD Disclosure StatementFebruary 2, 2024 | finance.yahoo.comZura Bio Announces Participation at February Investor ConferencesMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.January 8, 2024 | msn.comZura Bio appoints industry veteran Robert Lisicki as President and COOJanuary 8, 2024 | finance.yahoo.comZura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMOJanuary 3, 2024 | finance.yahoo.comZura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology SummitDecember 4, 2023 | finance.yahoo.comZura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in BangkokNovember 14, 2023 | finance.yahoo.comZura Bio Appoints Arnout Ploos van Amstel to its Board of DirectorsNovember 13, 2023 | msn.comZura Bio GAAP EPS of -$0.18November 13, 2023 | finance.yahoo.comZura Bio Reports Third Quarter 2023 Financial Results and Recent Business HighlightsOctober 11, 2023 | msn.comLadenburg Thalmann Initiates Coverage of Zura Bio Ltd - (ZURA) with Buy RecommendationSeptember 12, 2023 | finance.yahoo.comZura Bio Enters into Sponsored Research Agreement with Benaroya Research InstituteSeptember 7, 2023 | barrons.comZura Bio Ltd. WtSeptember 7, 2023 | finance.yahoo.comWe're Hopeful That Zura Bio (NASDAQ:ZURA) Will Use Its Cash WiselyAugust 25, 2023 | msn.comOppenheimer starts Zura Bio at outperform, cites potential of ZB-106August 25, 2023 | msn.comOppenheimer Initiates Coverage of Zura Bio Ltd - (ZURA) with Outperform RecommendationAugust 15, 2023 | msn.comRaymond James Maintains Zura Bio Ltd - (ZURA) Strong Buy RecommendationAugust 15, 2023 | markets.businessinsider.comWhere Zura Bio Stands With AnalystsAugust 14, 2023 | finance.yahoo.comZura Bio Reports Second Quarter 2023 Financial Results and Recent Business HighlightsJuly 20, 2023 | seekingalpha.comZURAW Zura Bio Limited WT EXP 032028June 23, 2023 | benzinga.comZura Bio shares are trading lower Wednesday amid possible profit-taking after the stock rallied on Tuesday.See More Headlines Receive ZURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zura Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ZURA CUSIPN/A CIK1855644 WebN/A Phone858-247-0520FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$16.60 High Stock Price Target$22.00 Low Stock Price Target$10.00 Potential Upside/Downside+588.8%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$3.55 million Net MarginsN/A Pretax MarginN/A Return on Equity-74.71% Return on Assets-38.33% Debt Debt-to-Equity RatioN/A Current Ratio6.15 Quick Ratio6.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$1.10 per share Price / Cash Flow2.20 Book Value($2.21) per share Price / Book-1.09Miscellaneous Outstanding Shares43,090,000Free Float36,285,000Market Cap$103.85 million OptionableNot Optionable Beta0.63 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. David BradyHead of Business DevelopmentDr. Someit Sidhu M.D. (Age 34)Founder, CEO & Director Mr. Robert Lisicki (Age 56)President & COO Mr. Verender S. Badial (Age 52)Chief Financial Officer Dr. Gary Whale Ph.D. (Age 50)Chief Technology Officer Dr. Michael D. Howell Ph.D. (Age 46)Chief Scientific Officer & Head of Translational Science Ms. Kimberly Ann Davis (Age 56)Chief Legal Officer & Secretary Ms. Theresa Lowry (Age 50)Chief Human Resources Officer Dr. Kiran Nistala MBBS (Age 51)Ph.D., Chief Medical Officer & Head of Development More ExecutivesKey CompetitorsAthira PharmaNASDAQ:ATHAVigil NeuroscienceNASDAQ:VIGLCEL-SCINYSE:CVMProtalix BioTherapeuticsNYSE:PLXAlloVirNASDAQ:ALVRView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 311,716 shares on 3/11/2024Ownership: 1.288%Citadel Advisors LLCSold 19,706 shares on 2/15/2024Ownership: 1.608%Barclays PLCBought 21,406 shares on 2/15/2024Ownership: 0.055%Forefront Analytics LLCBought 6,765 shares on 2/15/2024Ownership: 0.049%Occudo Quantitative Strategies LPBought 20,786 shares on 2/15/2024Ownership: 0.048%View All Insider TransactionsView All Institutional Transactions ZURA Stock Analysis - Frequently Asked Questions Should I buy or sell Zura Bio stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zura Bio in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZURA shares. View ZURA analyst ratings or view top-rated stocks. What is Zura Bio's stock price target for 2024? 5 brokers have issued 12 month price targets for Zura Bio's stock. Their ZURA share price targets range from $10.00 to $22.00. On average, they anticipate the company's share price to reach $16.60 in the next year. This suggests a possible upside of 545.9% from the stock's current price. View analysts price targets for ZURA or view top-rated stocks among Wall Street analysts. How have ZURA shares performed in 2024? Zura Bio's stock was trading at $4.67 on January 1st, 2024. Since then, ZURA stock has decreased by 45.0% and is now trading at $2.57. View the best growth stocks for 2024 here. How were Zura Bio's earnings last quarter? Zura Bio Limited (NASDAQ:ZURA) issued its quarterly earnings results on Monday, November, 13th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.07. Who are Zura Bio's major shareholders? Zura Bio's stock is owned by a number of retail and institutional investors. Top institutional investors include Armistice Capital LLC (4.23%), Citadel Advisors LLC (1.61%), Vanguard Group Inc. (1.29%), Vanguard Group Inc. (1.29%), Charles Schwab Investment Management Inc. (0.42%) and Northern Trust Corp (0.39%). View institutional ownership trends. How do I buy shares of Zura Bio? Shares of ZURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZURA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyInvestors Alert: The Next Big Thing in Weight LossBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zura Bio Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.